RZQ-MC2

About Rezq Bio

Rezq Bio is a private, preclinical-stage biotech founded in 2021, pioneering a localized immunomodulation platform using dendritic cell therapies. Its lead program, RZQ-MC1 for early-onset Type 1 Diabetes, has completed a Phase 1A safety trial and is preparing for Phase 1B/2A, supported by a pipeline targeting colitis and transplant support. The company is targeting a large, underserved market in autoimmune diseases, beginning with T1D, which lacks disease-modifying treatments and affects millions globally. Its approach differentiates by aiming to restore immune tolerance locally without systemic immunosuppression.

Therapeutic Areas